ReviewEuropean journal of pain (London, England)2026
Evaluating FABP5 as a Therapeutic Target for Pain Management.
Review in European journal of pain (London, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
BACKGROUND AND
objectiveFatty acid-binding proteins (FABPs) are intracellular lipid transporters. Pharmacological inhibition of FABP5 is analgesic in preclinical visceral, inflammatory, neuropathic and joint pain models. Genetic knockout or knockdown of FABP5 induces analgesia in select visceral and inflammatory pain models. This review explores the current evidence supporting FABP5 modulation in pain. DATABASES AND DATA TREATMENT: We searched PubMed (January-August 2025) for studies relating to FABP5 modulation in pain. We used terms associated with inhibition, genetic ablation, analgesia, pain behaviours, pain models and associated signalling pathways.
resultsFABP5 inhibition mediates analgesia through various lipid-signalling receptors (cannabinoid receptor type 1 [CB
conclusionsWhilst preclinical data support the potential of FABP5 inhibitors as novel analgesics, further research into sex differences and chronic dosing in visceral and inflammatory pain models is warranted. Despite this, FABP5 inhibition may hold promise for non-opioid and non-steroidal management of painful conditions. SIGNIFICANCE STATEMENT: This review highlights fatty acid-binding protein 5 (FABP5) inhibition as a novel, non-opioid and non-steroidal analgesic strategy with multiple mechanisms of action, broad efficacy in preclinical pain models, and a favourable safety profile. FABP5 inhibition may offer promise for the treatment of complex painful conditions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.